Therapeutics Development and Assessment for Acute Respiratory Distress Syndrome 2020

DUBLIN, Aug. 26, 2020 /PRNewswire/ -- The "Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020" drug pipelines has been added to's offering.

The latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The pipeline guide provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 28, 22, 4, 50, 16 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Scope of the report:

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Acute Respiratory Distress Syndrome (Respiratory).
    --  The pipeline guide reviews pipeline therapeutics for Acute Respiratory
        Distress Syndrome (Respiratory) by companies and universities/research
        institutes based on information derived from company and
        industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Acute Respiratory
        Distress Syndrome (Respiratory) therapeutics and enlists all their major
        and minor projects.
    --  The pipeline guide evaluates Acute Respiratory Distress Syndrome
        (Respiratory) therapeutics based on mechanism of action (MoA), drug
        target, route of administration (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews the latest news related to pipeline
        therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Key report benefits:

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Acute Respiratory Distress Syndrome (Respiratory).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and
        focus of Indication therapeutics.
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered:

    --  Acute Respiratory Distress Syndrome - Overview
    --  Acute Respiratory Distress Syndrome - Therapeutics Development
    --  Acute Respiratory Distress Syndrome - Therapeutics Assessment
    --  Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics
    --  Acute Respiratory Distress Syndrome - Drug Profiles
    --  Acute Respiratory Distress Syndrome - Dormant Projects
    --  Acute Respiratory Distress Syndrome - Discontinued Products
    --  Acute Respiratory Distress Syndrome - Product Development Milestones

Companies Mentioned

    --  A6 Pharmaceuticals LLC
    --  AbbVie Inc
    --  Abivax SA
    --  Aerogen Ltd
    --  Aerpio Pharmaceuticals Inc
    --  Akebia Therapeutics Inc
    --  Alexion Pharmaceuticals Inc
    --  Algernon Pharmaceuticals Inc
    --  Ampio Pharmaceuticals Inc
    --  APEIRON Biologics AG
    --  Bayer AG
    --  Baylx Inc
    --  BeiGene Ltd
    --  BioCardia Inc
    --  Biocon Ltd
    --  BioMarck Pharmaceuticals Ltd
    --  Biophytis SA
    --  Biotest AG
    --  Biovista Inc
    --  Bioxytran Inc
    --  Bonac Corp
    --  Bonus BioGroup Ltd
    --  CohBar Inc
    --  Commence Bio Inc
    --  Curacle Co Ltd
    --  Cynata Therapeutics Ltd
    --  Cytopeutics Pte Ltd
    --  Diffusion Pharmaceuticals Inc
    --  Dimerix Ltd
    --  Edesa Biotech Inc
    --  Educell doo
    --  Emergent BioSolutions Inc
    --  Emtora Biosciences
    --  Eunoia Biotech LLC
    --  Evgen Pharma Plc
    --  Exvastat Ltd
    --  Faron Pharmaceuticals Oy
    --  FibroGenesis LLC
    --  Foresee Pharmaceuticals Co Ltd
    --  Grifols SA
    --  Hemarina SA
    --  Histocell SL
    --  Human Life CORD Japan Inc
    --  Hydra Biosciences Inc
    --  Iltoo Pharma
    --  Immune Regulation Ltd
    --  In2cure AB
    --  Insmed Inc
    --  IsletOne AB
    --  LTT Bio-Pharma Co Ltd
    --  MannKind Corp
    --  Matrix Biomed Inc
    --  Meridigen Biotech Co Ltd
    --  Mesoblast Ltd
    --  Neutrolis Inc
    --  Northern Therapeutics Inc
    --  Novellus Inc
    --  Noxopharm Ltd
    --  NS Pharma Inc
    --  Orbsen Therapeutics Ltd
    --  Oryzon Genomics SA
    --  PharmAbcine Inc
    --  Pharming Group NV
    --  PhaseBio Pharmaceuticals Inc
    --  Pluristem Therapeutics Inc
    --  Predictive Biotech Inc
    --  R Pharm
    --  Relief Therapeutics Holding AG
    --  Restore Therapeutics LLC
    --  Reven Pharmaceuticals Inc
    --  Roivant Sciences Ltd
    --  SFA Therapeutics LLC
    --  SolAeroMed Inc
    --  SynAct Pharma AB
    --  Syndax Pharmaceuticals Inc
    --  Thetis Pharmaceuticals LLC
    --  Trevena Inc
    --  Vasomune Inc
    --  Veru Inc
    --  Xfibra Inc

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets